Catherine Bovenizer

Cath has served as Senior Vice President of Finance and Business Operations since July 2020, and from the company’s inception through June 2020 she served as consulting Chief Financial Officer. Prior to joining Recludix, Ms. Bovenizer served as the Chief Financial Officer of Renova Therapeutics, a privately-held company focused on the development of gene and peptide therapies for the treatment of cardiovascular and metabolic diseases. She served as Vice President of Finance and Chief Accounting Officer of Apricus Biosciences, a publicly-traded biopharmaceutical company that merged with Seelos Therapeutics in January 2019. Ms. Bovenizer previously served as Executive Director of Finance and Corporate Controller for Ambit Biosciences, where she helped lead the company’s internal processes through its initial public offering and sale to Daiichi Sankyo in 2014. Earlier in her career, Ms. Bovenizer practiced as a public accountant with Coopers & Lybrand. Ms. Bovenizer is a Certified Public Accountant in the State of California. Ms. Bovenizer graduated magna cum laude with a BA in Economics, Accounting, and Literature from Claremont McKenna College, where she was inducted into Phi Beta Kappa.